Xenon Pharmaceuticals Inc. – Product Pipeline Review – H2 2011

Xenon Pharmaceuticals Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Xenon Pharmaceuticals Inc. - Product Pipeline Review - H2 2011” provides data on the Xenon Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Xenon Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Xenon Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• Xenon Pharmaceuticals Inc. - Brief Xenon Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Xenon Pharmaceuticals Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Xenon Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the Xenon Pharmaceuticals Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate Xenon Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of Xenon Pharmaceuticals Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the Xenon Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with Xenon Pharmaceuticals Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of Xenon Pharmaceuticals Inc. and identify potential opportunities in those areas.